|
|
| March 11, 2018: Dr. Brendan Everett and Dr. C. Michael Gibson Discuss: CANTOS - Anti-Inflammatory Therapy with Canakinumab and Incident |
Dr. Brendan Everett and Dr. C. Michael Gibson Discuss: CANTOS - Anti-Inflammatory Therapy
with Canakinumab and Incident Type 2 Diabetes: A Pre-Specified Key Secondary Endpoint of
the CANTOS Trial
TBD
[ Download video ] |
|
No comments have been submitted
|